Search results for "Vascular Endothelial Growth Factor Receptor-1"

showing 10 items of 17 documents

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

2019

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out…

0301 basic medicineOncologyTumor angiogenesisVascular Endothelial Growth Factor Amedicine.medical_specialtyVascular Endothelial Growth Factor BVEGF-A/BAngiogenesisPharmaceutical ScienceArticle03 medical and health sciencesangiogenesis0302 clinical medicineInternal medicineMedicineHumansAdenomyosisRNA MessengerVascular Endothelial Growth Factor Receptor-1integumentary systemNeovascularization Pathologicbusiness.industryEndometrial cancerCancerVEGFR-1/2tumor angiogenesismedicine.diseasePrognosisImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Endometrial Neoplasms030104 developmental biologymedicine.anatomical_structureadenomyosis030220 oncology & carcinogenesisCase-Control Studiesembryonic structuresendometrial cancercardiovascular systemImmunohistochemistryFemaleAnalysis of varianceNeoplasm GradingbusinessBiotechnologyBlood vesselCurrent Pharmaceutical Biotechnology
researchProduct

Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease.

2015

Background: Intention of the study is to assess the cardiovascular mortality of patients with coronary artery disease (CAD) with the biomarkers of angiogenesis PlGF and its endogenous inhibitor sFlt-1. Methods: The cohort included n = 1848 patients with CAD and 282 subjects without CAD. In 85 patients cardiovascular mortality, as combination of fatal myocardial infarction or any cardiac death, during a median follow-up duration of 3.9 years was reported. Results: In Kaplan–Meier curve analysis PlGF in rising thirds was not predictive regarding outcome (p = 0.54), the same was shown for sFlt-1 (p = 0.44). Cox regression for the fully adjusted model provided a hazard ratio (HR) of 0.8 (p = 0…

0301 basic medicinePlacental growth factorMalemedicine.medical_specialtyClinical BiochemistryCoronary Artery DiseaseKaplan-Meier Estimate030204 cardiovascular system & hematologyPregnancy ProteinsCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryNatriuretic Peptide BrainmedicineHumansMyocardial infarctionPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Proportional hazards modelbusiness.industryBiochemistry (medical)Hazard ratioMiddle Agedmedicine.diseasePrognosisPeptide FragmentsVascular endothelial growth factor030104 developmental biologyEndocrinologychemistryCohortCardiologyFemalebusinessSoluble fms-like tyrosine kinase-1Follow-Up StudiesBiomarkers in medicine
researchProduct

Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction

2014

ObjectiveTo determine the release kinetics of different biomarkers with potential as novel early ischaemic biomarkers in patients with acute coronary syndrome (ACS); it is difficult to establish the detailed release kinetics in patients with acute myocardial infarction (AMI).MethodsWe analysed the release kinetics of soluble fms-like tyrosine kinase (sFlt-1), ischaemia modified albumin (IMA), and heart-type fatty acid binding protein (hFABP) in patients with hypertrophic obstructive cardiomyopathy who were undergoing transcoronary ablation of septal hypertrophy (TASH), a procedure mimicking AMI. Consecutive patients (n=21) undergoing TASH were included. Blood samples were collected before T…

Ablation TechniquesMalemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCardiomyopathySerum albuminSerum Albumin HumanFatty Acid-Binding ProteinsFatty acid-binding proteinPredictive Value of TestsInternal medicineHumansMedicineMyocardial infarctionSerum AlbuminAgedImmunoassayVascular Endothelial Growth Factor Receptor-1biologybusiness.industryCardiomyopathy HypertrophicMiddle Agedmedicine.diseaseUp-RegulationKineticsEarly DiagnosisPredictive value of testsbiology.proteinCardiologyFemaleFatty Acid Binding Protein 3Myocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessFatty Acid Binding Protein 3BiomarkersHeart
researchProduct

Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with sur…

2018

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression leve…

AdultMale0301 basic medicineCancer ResearchAdolescentAngiogenesisVascular Endothelial Growth Factor CKaplan-Meier EstimateVEGFC expressionYoung Adult03 medical and health sciences0302 clinical medicineKDRBone Marrowhemic and lymphatic diseasesNeuropilin 1Biomarkers TumormedicineNRP1HumansGeneFLT1AgedChromosome AberrationsAcute myeloid leukemiaVascular Endothelial Growth Factor Receptor-1Cell growthbusiness.industryAdult Acute Myeloid LeukemiaHematologyVEGF signalingMiddle AgedPrognosismedicine.diseaseVascular Endothelial Growth Factor Receptor-2Neuropilin-1Leukemia Myeloid AcuteLeukemia030104 developmental biologymedicine.anatomical_structureOncologyVascular endothelial growth factor CMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchFemaleBone marrowbusinessLeukemia & Lymphoma
researchProduct

Effects of acute exercise and xanthine oxidase inhibition on novel cardiovascular biomarkers.

2013

Several sports have been associated with a postexercise increase of cardiac, liver, and skeletal muscle biomarkers of injury. Exhaustive or acute physical exercise causes an increased generation of reactive oxygen species, resulting in cellular injury. Thus, exercise and training may trigger pathophysiological changes in serum concentrations of a variety of biomarkers. In this study, we aimed to evaluate the variation of novel biomarkers of stress and cardiovascular disease such as copeptin, midregional part of proadrenomedullin (MR-proADM), growth differentiation factor 15 (GDF15), soluble vascular endothelial growth factor receptor, and placental growth factor along with uric acid before …

AdultMalemedicine.medical_specialtyXanthine OxidaseGrowth Differentiation Factor 15AllopurinolAllopurinolAdministration OralPhysical exercisePregnancy ProteinsPlacebochemistry.chemical_compoundAdrenomedullinCopeptinDouble-Blind MethodPhysiology (medical)Internal medicineSoccermedicineHumansEnzyme InhibitorsProtein PrecursorsXanthine oxidasesports; reactive oxygen species; allopurinolExercisePlacenta Growth Factorreactive oxygen speciesVascular Endothelial Growth Factor Receptor-1business.industryMyocardiumBiochemistry (medical)Public Health Environmental and Occupational HealthGlycopeptidesGeneral MedicinePeptide FragmentsUric AcidVascular endothelial growth factorEndocrinologychemistryAthletesUric acidGDF15sportsbusinessBiomarkersmedicine.drugTranslational research : the journal of laboratory and clinical medicine
researchProduct

Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome

2006

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a life-threatening condition associated with ovarian stimulation. Its pathophysiology is unknown and its treatment continues to be empirical. Early (E)- and late (L)-OHSS occur in women at risk, though not in all cases. Vascular endothelial growth factor (VEGF) is related to increased vascular permeability in OHSS. We analysed the dynamics of the VEGF system in E- and L-OHSS. METHODS A prospective cohort of women undergoing IVF-ICSI treatment were divided into groups. E-OHSS: Nonpregnant patients classified as women not at risk (group 1) (n = 11) and patients at risk who did not (group 2) (n = 18) and did (group 3) (n = 8) develop sever…

AdultOvulationVascular Endothelial Growth Factor Amedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectOvarian hyperstimulation syndromeVascular permeabilityOvaryFertilization in VitroBiologyCohort StudiesOvarian Hyperstimulation Syndromechemistry.chemical_compoundInternal medicineBlood plasmamedicineHumansalpha-MacroglobulinsSperm Injections IntracytoplasmicProspective cohort studyOvulationmedia_commonVascular Endothelial Growth Factor Receptor-1OvaryRehabilitationObstetrics and Gynecologymedicine.diseaseVascular endothelial growth factorEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryOocytesFemaleSoluble fms-like tyrosine kinase-1Human Reproduction
researchProduct

Comparative study of human colonic tumor-derived endothelial cells (HCTEC) and normal colonic microvascular endothelial cells (HCMEC): Hypoxia-induce…

2009

Colorectal carcinoma growth and progression is dependent on the vasculature of the tumor microenvironment. Tumor-derived endothelial cells differ functionally from their normal counterpart. For this reason we isolated microvascular endothelial cells from human colon cancer tissue (HCTEC) and compared them with endothelial cells from normal colonic tissue (HCMEC) of the same donor. Since hypoxia is a universal hallmark of carcinomas, we examined its effects on HCTEC of five patients in comparison with the corresponding HCMEC, with respect to the secretion of the soluble form of the two important vascular endothelial growth factor (VEGF) receptors, VEGFR-1 and -2. After dissociation by dispas…

Cancer ResearchPathologymedicine.medical_specialtyEndotheliumColonEnzyme-Linked Immunosorbent AssayCell SeparationBiologychemistry.chemical_compoundmedicineHumansCells CulturedTumor microenvironmentVascular Endothelial Growth Factor Receptor-1OncogeneMicrocirculationEndothelial CellsGeneral MedicineVascular Endothelial Growth Factor Receptor-2Cell HypoxiaEndothelial stem cellVascular endothelial growth factormedicine.anatomical_structureOncologychemistryApoptosisTumor progressionColonic NeoplasmsCancer researchTumor necrosis factor alphaOncology Reports
researchProduct

Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.

2008

This study aimed to define the co-expression pattern of target receptor tyrosine kinases (RTKs) in human esophageal adenocarcinoma and squamous cell cancer. The co-expression pattern of vascular endothelial growth factor receptor (VEGFR)1-3, platelet-derived growth factor receptor (PDGFR)alpha/beta and epidermal growth factor receptor 1 (EGFR1) was analyzed by RT-PCR in 50 human esophageal cancers (35 adenocarcinomas and 15 squamous cell cancers). In addition, IHC staining was applied for the confirmation of the expression and analysis of RTK localisation. The adenocarcinoma samples revealed VEGFR1 (97%), VEGFR2 (94%), VEGFR3 (77%), PDGFRalpha (91%), PDGFRbeta (85%) and EGFR1 (97%) expressi…

Cancer ResearchPathologymedicine.medical_specialtyReceptor Platelet-Derived Growth Factor alphaEsophageal NeoplasmsAdenocarcinomaReceptor tyrosine kinaseReceptor Platelet-Derived Growth Factor betaGrowth factor receptormedicineHumansEpidermal growth factor receptorVascular Endothelial Growth Factor Receptor-1biologyOncogeneCancerReceptor Protein-Tyrosine KinasesGeneral Medicinemedicine.diseaseVascular Endothelial Growth Factor Receptor-3ImmunohistochemistryVascular Endothelial Growth Factor Receptor-2ErbB ReceptorsOncologyEpidermoid carcinomacardiovascular systembiology.proteinCancer researchCarcinoma Squamous CellAdenocarcinomaPlatelet-derived growth factor receptorOncology reports
researchProduct

Analysis of Antiproliferative and Chemosensitizing Effects of Sunitinib on Human Esophagogastric Cancer Cells: Synergistic Interaction With Vandetani…

2009

The receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 1-3 (VEGFR1-3), are frequently expressed in gastric cancer and are putative therapeutic targets in this disease. We have investigated the anti-proliferative and chemosensitizing properties of the multitargeted small-molecule RTK inhibitors sunitinib and vandetanib in a panel of 4 human gastric and esophageal cancer cell lines. In the 1st instance, the expression of potential targets of these small-molecule inhibitors was examined by reverse transcriptase-polymerase chain reaction, western blotting, and flow cytometry. EGFR mRNA and protein was detected in all cases, …

Cancer ResearchUmbilical VeinsIndolesEsophageal NeoplasmsApoptosisVandetanibTyrosine-kinase inhibitorReceptor tyrosine kinasechemistry.chemical_compoundPiperidinesSunitinibMedicineDrug InteractionsEpidermal growth factor receptorPhosphorylationCells CulturedbiologySunitinibReverse Transcriptase Polymerase Chain ReactionDrug SynergismFlow CytometryErbB ReceptorsOncologyPhosphorylationDrug Therapy Combinationmedicine.drugSignal Transductionmedicine.medical_specialtymedicine.drug_classBlotting WesternAntineoplastic AgentsStomach NeoplasmsInternal medicineHumansPyrrolesPropidium iodideRNA MessengerProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-1business.industryCancermedicine.diseaseVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2EndocrinologychemistryCancer researchbiology.proteinQuinazolinesEndothelium VascularbusinessProto-Oncogene Proteins c-akt
researchProduct

Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines

2008

Adaptation to hypoxia, a universal hallmark of carcinomas, is a critical step for tumor cell survival and growth. One of the principal regulators of hypoxia-responsive pathways is the transcription factor hypoxia-inducible factor-1 alpha (HIF-1 alpha). Currently, it is known that tumoral production of members of the vascular endothelial growth factor (VEGF)-family (VEGFs) may promote tumor growth and progression by acting on carcinoma cells that express the cognate receptors (VEGFRs). However, the influence of hypoxia in the formation of such a tumoral VEGF/VEGFR loop is not completely understood. In the present study we examined the potential existence of a HIF-1 alpha/VEGF/VEGFR autocrine…

Cancer Researchmedicine.medical_specialtyLung NeoplasmsVascular Endothelial Growth Factor CCellBreast NeoplasmsBiologychemistry.chemical_compoundDownregulation and upregulationCell Line TumorInternal medicinemedicineHumansAutocrine signallingVascular Endothelial Growth Factor Receptor-1CarcinomaKinase insert domain receptorCell cycleHypoxia-Inducible Factor 1 alpha SubunitVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2Cell HypoxiaUp-RegulationGene Expression Regulation NeoplasticVascular endothelial growth factorAutocrine CommunicationHIF1AEndocrinologymedicine.anatomical_structureOncologyVascular endothelial growth factor CchemistryCancer researchColorectal NeoplasmsInternational Journal of Oncology
researchProduct